The aim of this study was to estimate the risk of further creatinine increase in patients with preexisting renal disease after the use of oral sodium phosphate (OSP) versus polyethylene glycol (PEG), and to study usage patterns of OSP in relation to renal function.
INTRODUCTION
Although oral sodium phosphate-containing bowel preparations (OSP) were found to be effective and safe in clinical trials (1, 2) , a number of well-documented case reports suggested a causal relationship between OSP use and renal dysfunction at least in individual cases (3) (4) (5) . Current mechanistic hypotheses focus on OSP-induced fluid and electrolyte imbalances causing an increased phosphate-calcium product and possibly also decreased renal perfusion, particularly when hydration is insufficient (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . In line with these hypotheses there are two distinct safety concerns, i.e., irreversible acute renal failure (acute phosphate nephropathy/nephrocalcinosis) and usually reversible renal dysfunction of variable degree. Risk factors for renal dysfunction after OSP use have been proposed and are listed in the product information; for example, the use of Fleet Phospho-soda EZ-Prep is not recommended in patients with clinically significant impairment of renal function, heart failure, or ascites, and special caution is recommended in the elderly, in patients taking medications known to affect renal perfusion or function, with dehydration, or those taking drugs that affect fluid and electrolyte balance. In addition, the need for adequate hydration is emphasized and there is a warning not to exceed the recommended dose.
Whereas clinical studies tend to include a healthier population than that later exposed in clinical practice and do not consider how "real-life" drug usage may affect the risk of adverse effects, case reports allow no quantification of adverse drug effects. Several observational studies have therefore studied the risk of renal dysfunction associated with OSP use in clinical practice (17) (18) (19) (20) (21) . Compared to polyethylene glycol (PEG) some studies found a similar risk (18, 21) , whereas one study reported an approximate doubling of the risk (19) . Data sources and methods differed among these observational studies, and a conflicting debate about the safety of OSP continues (22) (23) (24) .
In our own previous study, we found no significant difference in the risk of renal dysfunction after colonoscopy on comparing OSP with PEG (21) . In this study, patients with preexisting renal disease including all patients with an estimated glomerular filtration rate (GFR) below 60 ml/min were excluded, because we primarily aimed to study the risk of incident renal disease in those in whom OSP use was compatible with current recommendations. However, during the identification of the study population we found that a substantial proportion of OSP users had preexisting renal dysfunction. Therefore, usage patterns of OSP in clinical practice and the question whether preexisting renal function may modify the risk of (additional) renal dysfunction associated with OSP deserve further investigation.
With the current study, we now aimed to evaluate the risk of further creatinine increase in patients with preexisting renal dysfunction after the use of OSP or PEG for colonoscopy. Furthermore, we wanted to describe patient characteristics and usage patterns of OSP and PEG in relation to renal function.
METHODS

Data Source
Information for this study was derived from the procedure database of the Gastroenterology Department at Henry Ford Hospital (HFH), Detroit, MI and the administrative databases within the Henry Ford Health System (HFHS). The Gastroenterology database contains detailed information on colonoscopies including date, bowel cleansing preparation, and adequacy of preparation, as well as the medical record number as a unique patient identifier that allows linkage between the HFHS administrative databases and electronic medical records. The HFHS database contains information on medical care encounters, diagnoses, procedures, outpatient drug prescriptions, laboratory results and patient demographics. Additionally, for patients enrolled in Health Alliance Plan (HAP), an HFHS owned and operated health maintenance organization, external claims for care are also available. Drug prescriptions are coded using the National Drug Code (NDC) provided by the U.S. Food and Drug Administration (FDA). All diagnoses are coded using the International Classification of Diseases, Clinical Modification (ICD-9 CM) coding system; procedures are coded using the Current Procedural Terminology (CPT-4) coding system. All events are noted with the date on which the initial service was delivered. We also had access to original medical records and laboratory results of all patients enrolled in HAP.
The HFHS Human Rights Committee approved the study with a waiver of authorization.
Study Population
The study was conducted among the base population of all patients who had a colonoscopy at the HFHS Detroit center's gastroenterology clinic between February 1, 1999, and April 30, 2006 , who received oral bowel cleansing preparations containing either OSP (Phospho-soda, C.B. Fleet Company, Inc., Lynchburg, VA) or PEG (COLYTE, Schwarz Pharma, Inc., Milwaukee, WI) and were enrolled in the HAP for at least 6 months prior to and at least 4 wk postcolonoscopy. From these patients, we obtained all creatinine values determined within 60 days prior to and 14 days postcolonoscopy and calculated GFR estimates according to the Modification of Diet in Renal Disease (MDRD) study formula (25) . From this base population, we subsequently excluded patients according to the following criteria: diagnoses or claims related to dialysis within 6 months prior to colonoscopy (in dialysis patients creatinine values do not reflect renal function), no creatinine determination within 60 days prior to colonoscopy, last GFR before colonoscopy ≥60 ml/min, and/or no creatinine determination 14 days postcolonoscopy. This selection process assured that our final study population included only patients with preexisting renal dysfunction and sufficient information for identification and differential diagnostic evaluation of further renal impairment in relation to PEG or OSP exposure.
We also extracted additional electronic information on demographics, preexisting concomitant drug use, and comorbidities for all patients in the study population. Drug prescriptions within 3 months prior to colonoscopy were identified as a proxy for current drug use. For the identification of comorbidities, we searched for related diagnostic codes or procedures within 12 months prior to colonoscopy. In addition to specific conditions of interest, the diagnostic coding was used to calculate the Charlson comorbidity index. Originally developed to assess survival probability based on the inpatient medical record review, this methodology is also useful with administrative databases as a means of measuring underlying burden of illness (26, 27) .
Definition, Identification, and Validation of Cases
From the study population we identified all patients where plasma creatinine increased by at least 0.5 mg/dl within 14 days after colonoscopy versus the last value before colonoscopy. Restriction on a short observation period after colonoscopy was based on the assumption that renal dysfunction in relation to bowel preparation products would manifest soon thereafter and that particularly in patients with preexisting renal dysfunction who often also have other comorbidities, a longer time period would increase the risk of misclassifying creatinine increase because of other reasons or "natural" fluctuations as related to bowel preparation exposure. Two physicians and one pharmacist with expertise in causality assessment of suspected adverse drug reactions then reviewed the original clinical records (SR) or abstracted case summaries (JKJ and SPM) of these patients, while being blinded with regard to the bowel preparation agent used (this information is not part of the clinical records but was kept in the Gastroenterology database, which was later incorporated into the main dataset for the final analysis). Patients with an identifiable likely cause of further renal impairment other than bowel preparation were subsequently excluded. The remaining patients were considered as "idiopathic" cases of further renal impairment and therefore to have at least a possible causal relationship to colonoscopy with bowel preparation.
Data Analysis
We calculated the incidence of further renal impairment during the 14-day period after colonoscopy and estimated the unadjusted relative risk (RR) in patients receiving OSP versus PEG as the period incidence ratio for these two groups. We used multivariate logistic regression in order to calculate odds ratios as an estimate of relative risks and to control for the possible effects of patient demographics, drug use, and comorbidities at the time of colonoscopy. In addition, we used a propensity score methodology as an alternative way to control for confounding, i.e., we generated a logistic regression model that calculated a patient's propensity to receive OSP or PEG based on patient demographics, current drug use, and medical history. Subsequently, we used this propensity score as a continuous covariate in a logistic regression model that measured the association between bowel preparation and further renal impairment (28) . Data were analyzed using STATA Version 8.2 for MacOS X (STATA Corp. LP, College Station, TX).
RESULTS
Identification of the base population, study population, and cases are summarized in Figure 1 . We identified a base population of 9,482 patients with continuous health plan enrollment who underwent colonoscopy and used either OSP (N = 7,971) or PEG (N = 1,511) for bowel preparation. One hundred fifty-seven patients had a recent history of dialysis. Among the remaining patients, 553 out of 1,390 PEG users (39.8%) and 5,572 out of 7,935 OSP users (70.2%) had no recorded creatinine measurement within 60 days prior to colonoscopy; and also, among 2,916 OSP users with an age ≥65 yr, 1,874 (64.3%) had no creatinine measurement within 60 days prior to colonoscopy. Of the remaining 837 PEG and 2,363 OSP users, 319 (38.1%) and 362 (15.3%), respectively, had a GFR <60 ml/min. Finally, we excluded another 364 patients who had no creatinine determination within 14 days postcolonoscopy, leading to a study population of 317 patients.
Trends in bowel preparation use over time are presented in Figure 2 . As shown, in the base population, OSP was the preferred bowel preparation until about 2004; then, starting in 2004 and coincident with the publication of several reports of renal failure after OSP use (3, 5) , relative use of OSP decreased from 88.0% before 2004 to 48.4% in 2006. In the study population, which includes only patients with a GFR <60 ml/min, relative use of OSP was lower, i.e., 49.1% until 2004, and there was a further decrease in its relative use going down to 7.1% in 2006.
The proportion of patients with an available creatinine value within 60 days before OSP use over time is presented in Figure 3 . As shown, there was no trend toward increased determinations of creatinine before OSP exposure over time; a similar pattern was found when looking only at patients with an age ≥65 yr (data not shown).
Demographics and baseline characteristics of the study population are presented in Table 1 . Compared to patients receiving OSP, a higher proportion of patients receiving PEG had a very low GFR below 30 ml/min, heart failure, and other comorbidities according to the Charlson index. They were also more likely to have colonoscopy as an inpatient procedure.
Within the study population, we identified 20 patients with an increase in creatinine of at least 0.5 mg/dl within 14 days after colonoscopy, based on the last creatinine value before and the first value after colonoscopy. Eleven patients had other identifiable causes for renal dysfunction and were therefore not included as cases; detailed reasons for not classifying those patients as cases are listed in Table 2 . Among the remaining nine cases, creatinine eventually returned to baseline in six patients, but did not do so during follow-up of more than 1 yr in three patients (one PEG and two OSP users). One patient with a baseline creatinine of 3.9 mg/dl had creatinine values above 5 mg/dl during follow-up and finally progressed to end-stage renal disease, and in the other two patients, creatinine remained high at around 2.5 mg/dl (baseline 1.3 mg/dl) and 3.5 mg/dl (baseline 2.7 mg/dl), respectively. In order to account for the possibility of a delayed increase in creatinine, we also reviewed the records of another 25 patients with a creatinine increase ≥0.5 mg/dl within 14 days after colonoscopy, but where the first creatinine value after colonoscopy was less than 0.5 mg/dl above the baseline value; however, an alternative plausible cause for these creatinine increases was identified in all those patients. Likely Cause for Renal Dysfunction 1. Creatinine increase started before colonoscopy associated with urinary tract infection, heart failure, and pneumonia 2. Obstructive uropathy; recovery of renal function after the passage of urinary catheter 3. Hospital admission in unstable condition with diabetic ketoacidosis and foot gangrene; discharge letter also mentions acute renal failure secondary to nephrotoxic immunosuppressive drugs 4. Discharge letter describes dehydration with acute tubular necrosis before colonoscopy 5. Admitted in unstable condition with diabetes and severe anemia requiring transfusion. Pronounced fluctuations of creatinine values before colonoscopy 6. Neurogenic bladder with urinary retention 7. Creatinine increase started before colonoscopy associated with dehydration and acute heart failure 8. Pronounced fluctuations of creatinine values before colonoscopy associated with decompensated heart failure and with anemia followed by forced diuresis 9. Pronounced fluctuations of creatinine values before colonoscopy associated with rectal bleeding with severe anemia requiring transfusion and decompensated heart failure treated with forced diuresis 10. Very high creatinine values above 6 mg/dl with pronounced fluctuations before colonoscopy. Medical records indicate recent dialysis treatment 11. After colonoscopy infection requiring antibiotic treatment with clindamycin and ciprofloxacin plus intravenous fluids for dehydration Absolute and univariate relative risks of impaired renal function after colonoscopy in relation to baseline characteristics are presented in Table 3 . As shown, use of OSP was significantly associated with further renal impairment when compared with PEG, but none of the other factors showed a significant association, either in the univariate or in the multivariate analyses. Adjusted relative risk estimates are presented in Table 4 . Regardless of whether conventional logistic regression or a propensity score methodology was used to control for confounding, adjusted relative risk estimates were similar to the unadjusted univariate relative risk and .2-9.9) * At least 0.5 mg/dl creatinine increase within 14 days after colonoscopy. † Risk of ≥0.5 mg/dl creatinine increase in patients with or without factor. ‡ Unadjusted relative risk ( = risk ratio) of ≥0.5 mg/dl creatinine increase after colonoscopy for the presence versus the absence of factor. § Diagnoses within 12 months prior to colonoscopy. ¶ Prescriptions within 3 months prior to colonoscopy. $ Angiotensin-converting enzyme inhibitors or angiotensin renin blockers.
indicated an elevated risk of renal impairment after the use of OSP versus PEG.
DISCUSSION
Several observational studies have evaluated the risk of renal dysfunction associated with OSP use. Two such studies, one of which did and one did not find an association of OSP with impaired renal function, included patients with creatinine increases without a patient-level medical record review for likely alternative causes (17, 20) ; furthermore, one of those studies modeled GFR changes as a continuous outcome and used a control group without colonoscopy, which provides only limited control over indication bias (20) . Among three other studies, one reported an elevated risk with an odds ratio 12.6 (1.5-106.5) * Adjusted odds ratios and 95% confidence intervals estimated from a logistic regression model in the case of creatinine increase as the outcome variable and the following cofactors: OSP use, age ≥65 yr, female gender, African-American race, baseline GFR <30 ml/min, congestive heart failure, diabetes mellitus, Charlson comorbidity score ≥4, inpatient colonoscopy, current use of angiotensin-converting enzyme inhibitors or angiotensin renin blockers, calcium channel blockers, and diuretics.
† Propensity score predicting the likelihood of PEG or OSP use conditional on all other cofactors listed above for the conventional logistic regression model; this score was then used as a covariate in a logistic regression model where the case of creatinine increase was the outcome variable and OSP exposure a cofactor. of 2.35 (95% CI 1.51-3.66), whereas the other two found no increased risk of renal dysfunction on comparing OSP with PEG (18, 21) . Data sources and methods including the exact outcome definition of renal dysfunction differed among these observational studies, which may provide an explanation for different results, but it is also worth mentioning that confidence intervals for risk estimates overlap among all three studies, and differences may therefore also be due to chance. Although all three studies had included only a limited number of patients and were therefore not sufficiently powered to detect differences for small absolute risks in the range of 1:1000 or less, they are reassuring in the sense that in spite of convincing case reports of renal failure after OSP use, these indeed appear to be rare events in patients without preexisting renal dysfunction. Nevertheless, it has been clearly shown that OSP can cause fluid and electrolyte imbalances, and it is also physiologically plausible that these may subsequently lead to renal dysfunction, particularly in patients with preexisting risk factors (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . In that context, it is of particular interest that the current study is the first that focused on a subpopulation with a preexisting low GFR and limited the follow-up time to a short at-risk period of only 14 days. On the one hand, this led to a limited number of patients who could be included in the final study population and consequently also limited the statistical precision of relative risk estimates. On the other hand, the likelihood of case misclassification because of other factors is decreased with a shorter follow-up time, particularly in patients with preexisting renal dysfunction with high intraindividual variability of creatinine values and most likely also a higher burden of comorbidities, which may themselves be associated with renal dysfunction. Also, previous case reports as well as current mechanistic hypotheses suggest that renal dysfunction, should it be caused by OSP, occurs within days after colonoscopy. Therefore, this restrictive study design is an important and robust method to control for confounding. Furthermore, although we realize intrinsic limitations of observational nonrandomized studies, ethical reasons would preclude the exposure of patients with preexisting significant renal impairment to OSP in a randomized clinical trial, leaving an observational study as the only option to study OSP's renal safety in this population. Our current study found a statistically significant association between OSP use and further substantial increase in creatinine values for patients with a preexisting GFR <60 ml/min in the unadjusted as well as in two separate adjusted analyses. Whereas the conventional logistic regression model may be unstable for our dataset where the number of covariates is high in relation to cases, the propensity score-based regression analysis can be expected to offer an advantage for the analysis of our data and should provide reasonable additional control of potentially confounding factors. Furthermore, none of the other covariates had a significant association with creatinine increase after OSP use, either in the univariate analysis or in the multivariate model. Therefore, in spite of limited patient numbers and consequently wide confidence intervals, our results do indicate an association between OSP use and further renal dysfunction in patients with a preexisting GFR <60 ml/min. This is an important finding that certainly supports current warnings not to use OSP in patients with preexisting renal disease. Interestingly, on the basis of renal phosphate handling kinetics Mishra et al. postulated that a GFR below 50 ml/min may be a threshold for the development of significant hyperphosphatemia after commonly used OSP doses (13) . As far as other possible risk factors are concerned, we incorporated information on these factors in the propensity score analysis in order to achieve reliable control for possible related confounding regarding the risk estimate for OSP versus PEG use. However, one must consider that the reported univariate unadjusted risks for these factors are subject to confounding and furthermore based on low numbers of cases with these factors. As mentioned above, the conventional multivariate regression model is not sufficiently reliable, and our study therefore does not allow a reliable estimation of independent risks associated with these factors.
If preexisting renal disease modifies the effect of OSP use on renal function after colonoscopy, the drug usage patterns found in our study have important implications for the safe use of OSP in clinical practice. As seen in Figure 2 , the overall use of OSP decreased after 2004, and in patients with preexisting low GFR nonrecommended use decreased from about 50% to less than 10%, which occurred in close temporal relationship with safety warnings and labeling changes for OSP. It is therefore likely that these had an impact on OSP use in clinical practice, causing both an unspecific decrease of OSP use in patients without evidence for an increased risk of OSP-induced renal damage and the desired avoidance of OSP in patients with preexisting renal dysfunction. However, this trend was only documented for patients for whom recent creatinine values were available. Given that chronic renal impairment may remain clinically silent and undetected for a long time, it is worrisome that we did not observe a trend toward increased determinations of creatinine before OSP exposure, not even in OSP users with an age ≥65 yr. Although this patient group has a high prevalence of renal impairment (29) (30) (31) , screening for preexisting renal disease was apparently not done in the majority of patients. In the light of these findings, one may ask whether over-thecounter availability of OSP may play a role, which might make it difficult to identify contraindications for OSP use including preexisting renal disease, and therefore contribute to the high proportion of patients without recent creatinine determinations.
In summary, our results indicate that OSP use is associated with further and possibly irreversible creatinine increase in patients with preexisting renal impairment, whereas current evidence does not indicate an increased risk of renal dysfunction in OSP users without preexisting renal dysfunction when compared with PEG users. The drug usage pattern in clinical practice is a major issue in relation to the renal safety of OSP. In clinical practice, OSP use has recently decreased, but this change in drug use did not focus on at-risk populations. We must assume that a substantial number of patients with preexisting renal disease continue to be exposed to OSP because creatinine is not measured and renal dysfunction may therefore remain unrecognized. Therefore, it must be reemphasized that OSP should not be used in patients with moderate or severe renal impairment and that renal function should be monitored before and after colonoscopy in those at risk for renal dysfunction.
